There is phenomenal reduction in the incidence of mortality due to coronary artery disease from 1960 to 2015, which is reflected as lower incidence (0.2%) of PMIVSD. The mortality rate is more than 90% at the end of the first 2 months with current medical management. The natural history shows bimodal peak of occurrence of PMIVSD. The first and second peaks happen in 16-24 h and in 3 and 5 days after MI, respectively. The limited time interval between the detection of PMIVSD with cardiogenic shock and death is really a challenge to manage in the different hospital settings. The surgically treated patients suffer a mortality between 20% and 60%.
There is phenomenal reduction in the incidence of mortality due to coronary artery disease from 1960 to 2015, which is reflected as lower incidence (0.2%) of PMIVSD. The mortality rate is more than 90% at the end of the first 2 months with current medical management. The natural history shows bimodal peak of occurrence of PMIVSD. The first and second peaks happen in 16-24 h and in 3 and 5 days after MI, respectively. The limited time interval between the detection of PMIVSD with cardiogenic shock and death is really a challenge to manage in the different hospital settings. The surgically treated patients suffer a mortality between 20% and 60%. 1 The pre-operative hemodynamic stability improves mortality rate but guideline opposes this waiting. The operative mortality rate was 54% when the surgery was done within 7 days and it reduced to 18% when the surgery was done after 7 days. 1 The mortality was quite high when the surgery was done in an emergency basis, especially within 6 h of MI. The incidence of residual defect after surgical repair of post-MI VSR was noted to be around 10-40%. 2 The TCC of PMIVSD is very useful when done after a an interval of primary PCI, after 2-3 weeks of MI, residual leak closure after surgery, and as a bail out or salvage where surgical closure weighs more risk than benefit. 3,4 The residual shunting, ventricular rupture, device embolization, and adverse events experience during follow-up in some patients are seen in 41% of patients when TCC is done in acute (<2 weeks) and subacute (2-4 weeks) conditions. 4,5 The contraindications for transcatheter therapy include defect size >35 mm, basal VSR near mitral or aortic i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) 9 9 -1 0 1 a r t i c l e i n f o an article titled ''The novel use of heart transplantation for the management of a case with multiple complications following acute myocardial infarction'', first described the role of heart transplantation to salvage a patient of PMIVSR. Ari et al. 9 reported in 2012 percutaneous Closure of PMIVSR in a patient with left ventricular apical thrombus, as a first published report. The choice of occluder is no more restricted to dedicated PMIVSD occluder because of varying anatomy and difference of time intervention from operator to operator. 10 The waist size of PMIVSD occluder should comparatively be larger by 6-8 cm when the size of VSD is compared, because of their soft and friable border. The exact three-dimensional size and shape should be well perceived before intervention. The basic imaging tools are 2D and 3D echocardiography for diagnosis and intervention. In the cases of complicated anatomy, cardiac MRI would be complimentary or can replace left ventricular angiogram in this aspect. Transjugular approach is preferred to transfemoral approach. Balloon dilatation is usually discouraged in acute or subacute setting to assess the size of VSD. Risk stratification can be supported by EURO score. The contrast-induced nephropathy and device embolization following it should not be ignored in the acute and subacute setting because the intervention in these cases is all about hemodynamically unstable patients and friable border of PMIVSD. The meta-analysis reported by De Puy et al. 3 shows the procedural success rate of 80-90% with TCC.
There are two case reports and one small series has been reported from India. [10] [11] [12] Though there is drastic reduction in the incidence of PMIVSR with improvement in pharmacoinvasive therapy from 3% to 0.17% in APEX-MI registry, 13 this should neither encourage cardiologists to sit cross legged nor be completely biased by AHA/ACC decision saying that surgery is indicated in this condition irrespective of clinico-hemodynamic aspect. A scientist makes science and not the reverse. The device closure of PMIVSD is currently the second choice and is in the upslope of the learning curve. Indian researchers should take more initiative in this regard to add to the experience of transcatheter closure of PMIVSR using hemodynamic supportive measures like ECMO, Impella and IABP to improve periprocedural results. The results with surgical closure are closely similar to TCC. Therefore, TCC should be encouraged whenever hemodynamic condition and morphology are suitable to device closure. The coronary artery disease burden and certainly its related complication would arise in the coming days in India. Therefore, the cardiologist, as evidenced, should show interest in TCC as a viable alternative.
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